Pfizer and Medivation have reported unsuccessful results from a Phase III trial of investigational drug Dimebon (latrepirdine) in patients with Huntington’s disease.
The results revealed that Dimebon did not achieve statistical significance for either of the co-primary endpoints: the Mini-Mental State Examination, which measures cognition; or the Clinician’s Interview-Based Impression of Change plus care-giver input, which measures global function.
Go deeper with GlobalData
Dimebon was generally well-tolerated in the double-blind, placebo-controlled study, which enrolled 403 patients with Huntington’s at 64 sites in North America, Europe and Australia.
Patients were randomised to receive either 20mg of Dimebon three times a day or a placebo, for six months.
Following the result, the companies have decided to discontinue development of Dimebon as a treatment for Huntington’s disease, including the ongoing open-label extension study.
The oral medication is also developed for the treatment of Alzheimer’s disease.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData
